About this episode

The episode discusses the positive atmosphere at BIO 2026 in San Diego, highlighting changes at the FDA and issues surrounding Amgen's drug Tavneos.

The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivotal study for Amgen’s rare disease drug Tavneos, which has been in the FDA’s crosshairs since January.

Topics covered

• FDA changes
• dealmaking
• IPO trends
• Amgen Tavneos
• BIO conference
• medical journal retraction

Keywords

• BIO 2026
• FDA
• Amgen
• Tavneos
• dealmaking
• IPO
• medical journal

Mentioned in this episode

Organizations: FDA, Amgen

Products: Tavneos

Places: San Diego

More episodes of BioSpace

• The future of pain relief: Exploring opioid alternatives · July 16, 2026 · 19 min
• Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup · July 15, 2026 · 21 min
• Bonus: Q2 2026 Job Market Update · July 14, 2026 · 9 min
• From sequence to scale: Gene editing’s new era in biologics manufacturing · July 10, 2026 · 21 min
• Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil · July 8, 2026 · 17 min
• The Golden Triangle and the gaps: Rethinking UK biotech · June 25, 2026 · 20 min

Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.